CN115607646A - 一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法 - Google Patents
一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法 Download PDFInfo
- Publication number
- CN115607646A CN115607646A CN202211344433.XA CN202211344433A CN115607646A CN 115607646 A CN115607646 A CN 115607646A CN 202211344433 A CN202211344433 A CN 202211344433A CN 115607646 A CN115607646 A CN 115607646A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- blood
- traditional chinese
- effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 208000002399 aphthous stomatitis Diseases 0.000 title claims abstract description 56
- 208000007117 Oral Ulcer Diseases 0.000 title claims abstract description 43
- 230000000306 recurrent effect Effects 0.000 title claims abstract description 38
- 230000001684 chronic effect Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 143
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 34
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 32
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 32
- 235000013976 turmeric Nutrition 0.000 claims abstract description 32
- 241001646826 Isodon rubescens Species 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 27
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 22
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 22
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 22
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 22
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- 241000132012 Atractylodes Species 0.000 claims abstract description 20
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 19
- 235000011477 liquorice Nutrition 0.000 claims abstract description 19
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 18
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 18
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 18
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims abstract description 17
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract description 17
- 235000006533 astragalus Nutrition 0.000 claims abstract description 15
- 241000405414 Rehmannia Species 0.000 claims abstract description 14
- 238000005469 granulation Methods 0.000 claims abstract description 12
- 230000003179 granulation Effects 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 9
- 240000004980 Rheum officinale Species 0.000 claims abstract description 8
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 7
- 244000235603 Acacia catechu Species 0.000 claims abstract description 6
- 244000301850 Cupressus sempervirens Species 0.000 claims abstract description 4
- 230000008569 process Effects 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 15
- 241000218206 Ranunculus Species 0.000 claims description 14
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 244000077995 Coix lacryma jobi Species 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 5
- 241000906579 Actaea cimicifuga Species 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 244000081426 Ranunculus ficaria Species 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 235000014347 soups Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 165
- 239000008280 blood Substances 0.000 abstract description 105
- 210000004369 blood Anatomy 0.000 abstract description 104
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 75
- 201000010099 disease Diseases 0.000 abstract description 73
- 230000001737 promoting effect Effects 0.000 abstract description 69
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 55
- 208000026435 phlegm Diseases 0.000 abstract description 55
- 230000017531 blood circulation Effects 0.000 abstract description 32
- 230000001717 pathogenic effect Effects 0.000 abstract description 31
- 239000012528 membrane Substances 0.000 abstract description 29
- 201000007100 Pharyngitis Diseases 0.000 abstract description 21
- 239000000463 material Substances 0.000 abstract description 21
- 231100000331 toxic Toxicity 0.000 abstract description 21
- 230000002588 toxic effect Effects 0.000 abstract description 21
- 238000010926 purge Methods 0.000 abstract description 17
- 230000035876 healing Effects 0.000 abstract description 16
- 206010068319 Oropharyngeal pain Diseases 0.000 abstract description 14
- 238000001816 cooling Methods 0.000 abstract description 13
- 206010039424 Salivary hypersecretion Diseases 0.000 abstract description 5
- 208000026451 salivation Diseases 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 210000003800 pharynx Anatomy 0.000 description 39
- 230000036407 pain Effects 0.000 description 36
- 208000002193 Pain Diseases 0.000 description 35
- 238000011160 research Methods 0.000 description 35
- 210000000952 spleen Anatomy 0.000 description 35
- 210000004072 lung Anatomy 0.000 description 34
- 210000004185 liver Anatomy 0.000 description 30
- 230000006870 function Effects 0.000 description 28
- 210000004379 membrane Anatomy 0.000 description 28
- 210000002784 stomach Anatomy 0.000 description 28
- 230000002401 inhibitory effect Effects 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 25
- 208000011580 syndromic disease Diseases 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 23
- 230000007812 deficiency Effects 0.000 description 23
- 208000025865 Ulcer Diseases 0.000 description 22
- 239000000284 extract Substances 0.000 description 22
- 230000036039 immunity Effects 0.000 description 22
- 210000003734 kidney Anatomy 0.000 description 22
- 206010011224 Cough Diseases 0.000 description 21
- 230000000844 anti-bacterial effect Effects 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 20
- 235000019640 taste Nutrition 0.000 description 20
- 231100000397 ulcer Toxicity 0.000 description 20
- 235000009508 confectionery Nutrition 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- 230000001988 toxicity Effects 0.000 description 19
- 231100000419 toxicity Toxicity 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 241000219061 Rheum Species 0.000 description 17
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 17
- 230000003110 anti-inflammatory effect Effects 0.000 description 17
- 230000008961 swelling Effects 0.000 description 17
- 244000080767 Areca catechu Species 0.000 description 16
- 239000000306 component Substances 0.000 description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 238000009825 accumulation Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 150000004676 glycans Chemical class 0.000 description 14
- 244000052769 pathogen Species 0.000 description 14
- 229920001282 polysaccharide Polymers 0.000 description 14
- 239000005017 polysaccharide Substances 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 230000003213 activating effect Effects 0.000 description 13
- 210000000038 chest Anatomy 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 208000004880 Polyuria Diseases 0.000 description 12
- 241001530126 Scrophularia Species 0.000 description 12
- 230000035619 diuresis Effects 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 12
- 210000000214 mouth Anatomy 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 210000001124 body fluid Anatomy 0.000 description 11
- 239000010839 body fluid Substances 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 9
- 208000027744 congestion Diseases 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000008506 pathogenesis Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000010415 tropism Effects 0.000 description 9
- 241001061264 Astragalus Species 0.000 description 8
- 206010010774 Constipation Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 210000004233 talus Anatomy 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 208000004998 Abdominal Pain Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 206010028034 Mouth ulceration Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 235000012754 curcumin Nutrition 0.000 description 7
- 229940109262 curcumin Drugs 0.000 description 7
- 239000004148 curcumin Substances 0.000 description 7
- -1 decoction Substances 0.000 description 7
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 210000000867 larynx Anatomy 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- SDHTXBWLVGWJFT-XKCURVIJSA-N oridonin Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12[C@@H](O)CCC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 SDHTXBWLVGWJFT-XKCURVIJSA-N 0.000 description 7
- CAQAFLRZJHXSIS-UHFFFAOYSA-N oridonin Natural products CC1(C)C=CC(O)C23COC(O)(C(O)C12)C45C(O)C(CCC34)C(=C)C5=O CAQAFLRZJHXSIS-UHFFFAOYSA-N 0.000 description 7
- 231100000915 pathological change Toxicity 0.000 description 7
- 230000036285 pathological change Effects 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241000721047 Danaus plexippus Species 0.000 description 6
- 206010013789 Dry throat Diseases 0.000 description 6
- 201000008197 Laryngitis Diseases 0.000 description 6
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 208000007107 Stomach Ulcer Diseases 0.000 description 6
- 241000194019 Streptococcus mutans Species 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 201000005917 gastric ulcer Diseases 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 210000001260 vocal cord Anatomy 0.000 description 6
- 206010000077 Abdominal mass Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 5
- 244000150195 Cyperus longus Species 0.000 description 5
- 241000972673 Phellodendron amurense Species 0.000 description 5
- 206010040925 Skin striae Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 208000031971 Yin Deficiency Diseases 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000009243 chronic laryngitis Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010013952 Dysphonia Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 208000010473 Hoarseness Diseases 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 229940107666 astragalus root Drugs 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000005757 colony formation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000000188 diaphragm Anatomy 0.000 description 4
- 230000003467 diminishing effect Effects 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 201000009240 nasopharyngitis Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 241000092665 Atractylodes macrocephala Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- KVRQGMOSZKPBNS-FMHLWDFHSA-N Harpagoside Chemical compound O([C@@H]1OC=C[C@@]2(O)[C@H](O)C[C@]([C@@H]12)(C)OC(=O)\C=C\C=1C=CC=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KVRQGMOSZKPBNS-FMHLWDFHSA-N 0.000 description 3
- KVRQGMOSZKPBNS-BYYMOQGZSA-N Harpagoside Natural products C[C@@]1(C[C@@H](O)[C@@]2(O)C=CO[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]12)OC(=O)C=Cc4ccccc4 KVRQGMOSZKPBNS-BYYMOQGZSA-N 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 208000006877 Insect Bites and Stings Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- 240000005001 Paeonia suffruticosa Species 0.000 description 3
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 3
- 241000972672 Phellodendron Species 0.000 description 3
- 208000037062 Polyps Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 241000270295 Serpentes Species 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000004078 Snake Bites Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000002390 hyperplastic effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000003516 pericardium Anatomy 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000001543 purgative effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028124 Mucosal ulceration Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 240000002948 Ophiopogon intermedius Species 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000405911 Rehmannia glutinosa Species 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 239000004187 Spiramycin Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000002365 anti-tubercular Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000002747 omentum Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 210000004224 pleura Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000019614 sour taste Nutrition 0.000 description 2
- 229960001294 spiramycin Drugs 0.000 description 2
- 235000019372 spiramycin Nutrition 0.000 description 2
- 229930191512 spiramycin Natural products 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 208000023409 throat pain Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- QEBNYNLSCGVZOH-NFAWXSAZSA-N (+)-valencene Chemical compound C1C[C@@H](C(C)=C)C[C@@]2(C)[C@H](C)CCC=C21 QEBNYNLSCGVZOH-NFAWXSAZSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 239000001890 (2R)-8,8,8a-trimethyl-2-prop-1-en-2-yl-1,2,3,4,6,7-hexahydronaphthalene Substances 0.000 description 1
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- DQTBTFHCLVMGBP-UHFFFAOYSA-N (Z)-p-coumaroylaucubin Natural products OC1C(O)C(O)C(CO)OC1OC1C2C(COC(=O)C=CC=3C=CC(O)=CC=3)=CC(O)C2C=CO1 DQTBTFHCLVMGBP-UHFFFAOYSA-N 0.000 description 1
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 240000000559 Albizia odoratissima Species 0.000 description 1
- 235000011438 Albizia odoratissima Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 244000075634 Cyperus rotundus Species 0.000 description 1
- 235000016854 Cyperus rotundus Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- SSFSGTBTPVWUPA-UHFFFAOYSA-N Eurostoside Natural products OCC1OC(OC2OC=CC3(O)C(O)C=C(COC(=O)C=Cc4ccc(O)cc4)C23)C(O)C(O)C1O SSFSGTBTPVWUPA-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 102000000849 HMGB Proteins Human genes 0.000 description 1
- 108010001860 HMGB Proteins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101710185235 High mobility group protein 1 Proteins 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241001183967 Isodon Species 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- VYZAGTDAHUIRQA-WHFBIAKZSA-N L-alanyl-L-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-WHFBIAKZSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 101710180313 Protease 3 Proteins 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000976858 Rheum tanguticum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 241001537924 Tetracoccus <angiosperm> Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000218989 Trichosanthes Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- DQTBTFHCLVMGBP-WXUDOLSOSA-N [(1s,4ar,5s,7as)-5-hydroxy-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-7-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(COC(=O)\C=C\C=3C=CC(O)=CC=3)=C[C@@H](O)[C@@H]2C=CO1 DQTBTFHCLVMGBP-WXUDOLSOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 201000010550 acute laryngitis Diseases 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 101150024147 bax gene Proteins 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 229940045373 chlorhexidine mouthwash Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 229940104299 cimicifugae rhizoma Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 108010012173 hypophysin Proteins 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 235000020068 maotai Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940077150 progesterone and estrogen Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- WCTNXGFHEZQHDR-UHFFFAOYSA-N valencene Natural products C1CC(C)(C)C2(C)CC(C(=C)C)CCC2=C1 WCTNXGFHEZQHDR-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法,属于中药领域,由以下组分的原料制备而成:冬凌草10‑50份、猫爪草6‑15份、瓜蒌10‑20份、薄荷6‑15份、香附9‑15份、麦冬10‑20份、黄芪15‑50份、白术9‑15份、薏苡仁10‑50份、姜黄9‑15份、大黄6‑15份、儿茶3‑10份、熟地黄10‑20份、黄柏6‑15份、玄参9‑20份、牡丹皮9‑15份、姜黄6‑15份、升麻9‑15份、乌梅6‑15份、甘草9‑20份。本发明中药组合物遵循“三焦焦膜”理论;采用异病同治的方法;组合物具有清热解毒化湿、泻火、凉血、利咽,益气养阴生津,活血化瘀,化痰散结,敛疮生肌等功效;该中药组合物简便、价廉且无毒无副作用;该中药组合物服用方便,可使用现代工艺制备成多种剂型服用,此外还可批量生产,推广使用。
Description
技术领域
本发明涉及中药技术领域,特别涉及了一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法。
背景技术
复发性口腔溃疡(Recurrent Oral Ulcer, ROU)又称阿弗他溃疡(RecurrentAphthous Ulcer, RAU)是常见的口腔黏膜病,其近几年患病率高达20%左右。该病呈周期性复发,间歇期长短不一。早期黏膜上皮细胞内及细胞间水肿,可形成上皮内疱。上皮内及血管周围有密集的淋巴细胞、单核细胞浸润,随后有多形核白细胞、浆细胞浸润,上皮溶解破溃脱落,形成溃疡。溃疡表面有纤维素性渗出物形成假膜或坏死组织覆盖。固有层内胶原纤维水肿变性、均质化或弯曲断裂,甚至破坏消失。炎症细胞大量浸润。毛细血管充血扩张,血管内皮细胞肿胀,管腔狭窄甚至闭塞,有小的局部性坏死区,或见血管内玻璃样血栓。重型阿弗他溃疡可深及黏膜下层。复发性阿弗他溃疡多为轻型,重型及疱疹型较少。轻型为孤立的圆形或椭圆形浅表溃疡,直径一般为2〜4mm , 周界清晰,数目不多,每次1〜5个不等。好发于唇、颊、舌等黏膜。前驱期黏膜局部不适,触痛或灼痛感;约24小时后出现白色或红色疹状小点;2〜3天后上皮破损,进入溃疡期;整个发作期一般持续1〜2周。该病有自愈性,发作间期一般初发较长,此后逐渐缩短,因刺激影响语言、进食、心情,常给患者带来各种痛苦和不便,尤其对频繁发作者生活质量产生较大影响。
目前,口腔溃疡的病因及致病机制仍不明确。现代医学认为,口腔溃疡的发作有70%与免疫因素有关。精神紧张、内分泌失调、营养失衡等因素都有可能引起免疫力低下,从而使细胞抵抗外界侵害的能力下降,引发口腔溃疡。流行病学调查发现,复发性口腔溃疡遗传率75%,仅次于精神分裂症80%的遗传率。有学者发现父母均无复发性口腔溃疡,其子女的发病率为12%-29%,父母一方患复发性口腔溃疡的发病率为30%-40%,而父母均患复发性口腔溃疡的子女发病率为62%-70%o而国外学者的研究结果也与此相近。说明复发性口腔溃疡是一种多基因遗传病。相对稳定的生物钟会在中枢神经系统形成固定的排序,从而决定免疫细胞的正常分泌。口腔是人体菌群最多的一个部位,生物钟一旦被打破,会造成免疫细胞分泌紊乱,而T细胞等免疫细胞分泌的减少和免疫功能受抑制。会直接造成口腔菌群紊乱,从而引发溃疡。口腔与消化道、胃肠等同属消化系统,而消化道溃疡、胃溃疡、十二指肠溃疡、胆道疾病和慢性肝损害等疾病均有可能出现口腔溃疡的表现。有专家对部分复发性口腔溃疡患者做检查,发现了食管、胃、十二指肠溃疡的致病因素幽门螺杆菌。女性在排卵期会引起激素水平,如孕酮、雌激素的轻微波动,这种波动会给女性带来一系列的身体表现,包括痛经、失眠、性情改变等,其中之一就是口腔溃疡,这种溃疡又称为“经前溃疡”,通常在月经来潮之前发病。当人们面临升学考试、工作变动、家庭变故时,常会引出一系列的生理反应,如饮食失衡、心烦意乱、失眠等。生活失调带来的是神经系统功能紊乱,导致身体免疫力的低下,从而给口腔溃疡的发病创造了条件。由于病因不明,口腔溃疡的诊断完全是基于病史及临床表现,缺少可作为确诊依据的实验室指标。口腔溃疡预示着机体可能有潜在系统性疾病,如胃肠、血液和内分泌系统的疾病,但临床上大部分患者身体健康,无系统性疾病。治疗上,现代医学多选用局部治疗常选用抗菌、抗病毒、止痛、肾上腺皮质激素及免疫调节剂等药物:①消炎药物:甲硝唑、替硝唑、庆大霉素、氧氟沙星、环丙沙星、新霉素、金霉素、林可霉素等。抗霉菌药物一般选用克拉霉素、制霉菌素、酮康哇等;抗病毒药物如阿昔洛韦等。②皮质激素类药物:泼尼松、地塞米松、氢化可的松等,该类药物是大部分药膜的主要有效成分。③消毒防腐药:氯己定(双氯苯双弧己烷)或醋酸氯己定等。④免疫抑制剂和免疫调节剂,但用于口腔膜剂的研究较少。⑤局部止痛药物:达克罗宁、丁卡因、可卡因等可迅速减轻患者溃疡部位疼痛且有利于溃疡面愈合。⑥促进溃疡愈合的药物:维A酸、鱼肝油、维生素E、核黄素、维生素C、硫酸锌、磺胺嘧啶、葡萄糖酸等药物治疗,可获得一定疗效,但疗程较长,且抗霉菌等药物副作用大,病情易反复发作。
近年来的研究发现,RAU 的结缔组织中呈局灶性的白细胞碎屑性血管炎,具Arthus 型损害,这提示 RAU与变应性血管炎有关,变应性血管炎也称过敏性血管炎,白细胞破碎性血管炎,变硬性脉管[23]其特征是小血管毛细血管受累,血壁有中性粒细胞浸润和粒细胞破碎,血管壁坏死,并有纤维蛋白物质沉积,临床表现则以皮肤和黏膜溃疡病损为主。中医辨证认为,变应性血管炎的病机在于气滞血瘀,阻滞脉道,血流不通而渗于脉外。瘀滞日久生则新血不生,或湿热日重,热毒阻络,灼伤脉络,迫血妄行,因而使黏膜和皮肤失于濡养。因此,我们从中医辨证施治出发,以清热利湿,活血解毒为主要治疗方法。
复发性口腔溃疡属中医“口疮”、“口疡”等范畴。“口疮”之名始见于《内经》。《素问•气交变大论》曰:“岁金不及,炎火上行……民病口疮,甚则心痛。”指出口疮以火热为邪。后历代医家又有深层认识,《丹溪心法•口齿》篇曰:“口疮,服凉药不愈者,因中焦土虚,且不能食,相火冲上无制。”指出脾气虚弱与口疮的关系。清朝齐秉惠《齐氏医案•口疮》认为:“口疮上焦湿热,中焦虚寒,下焦阴火,各经传遍所致,当分辨阴阳虚实寒热而治之。”《寿世保元•口舌》日:“口疮者,脾气凝滞加之风热而然也。”以上分别指出上焦实火熏灼、下焦阴火上炎、中焦虚寒或脾虚湿困皆为本病之病机,须辨病求因而治。其病机也为本专利申请运用“三焦焦膜”理论治疗复发性口腔溃疡提供了理论基础。
咽喉炎是临床上的常见病和多发病,有急、慢性之分,属于上呼吸道感染的一部分。咽喉炎的病变主要在黏膜层,表现为咽部黏膜慢性充血,其血管周围有较多淋巴细胞浸润,也可见白细胞及浆细胞浸润。其常见症状有喉感不适、发声改变、咳嗽咽喉痒等。
现代医学认为,咽喉为人体重要的免疫器官,许多感染性疾病和免疫性疾病都与咽喉有密切关系。咽是人体与外界相通的要道,具有重要的防御、呼吸、吞咽、发声共鸣等功能。咽的急、慢性咽喉炎导致的病理改变,不仅造成咽局部的机能障碍,也可波及邻近器官组织,甚至影响全身其他系统,损害人体健康。急性咽喉炎时,除咽痛外,还可出现发热、怕冷、头痛、周身酸痛、食欲差,大便干、口干渴等全身中毒反应。有细菌感染时,血液白细胞数升高。如果咽喉炎咽痛剧烈,影响吞咽,还会造成体内营养、代谢失调。病因:咽喉炎的致病病因复杂,但主要可归究于以下几个方面:生活习惯方面、饮食习惯方面、环境因素等。这三个方面属外因,内因则包括自身健康状况、相关疾病的治疗情况等。大多数患者都是由内因和外因相互作用造成的,也有的患者是由二者之其中一种造成的,所以对于慢性咽喉炎患者来讲,如果不能及时注意和纠正生活中的一些不良习惯和细节将使病情不断加重并严重地影响治疗效果。临床采取抗菌、抗病毒、手术等方式治疗急性咽喉炎,对于慢性咽喉炎西医也仅仅能对症治疗,效果不满意。
如果咽喉炎治疗不及时,或反复发作,可转为慢性;若感染向上蔓延,波及耳、鼻,可导致急性鼻炎、鼻窦炎,急性中耳炎;向下发展,可侵犯喉、气管等下呼吸道,引起急性喉炎、气管炎、支气管炎及肺炎;若致病菌及毒素侵入血液循环,则可引起全身并发症,如急性肾炎、脓毒血症、风湿病等,对身体危害极大。患了慢性咽炎的人经常感到咽部不适,稍一受凉、劳累,或讲话多、较长时间没喝水,便觉咽痛、灼热加重,咽痒引起阵阵刺激性咳嗽,影响休息。若是干燥或萎缩性咽喉炎,则咽干明显,讲话和咽唾液也感费劲,需频频饮水湿润,甚至夜间也需要起床喝几次水,但也只能暂时缓解症状,很快就又感咽干;有的人吃饭时需用汤水才能将干硬的食物咽下去。
咽喉炎属中医“喉痹”范畴。根据中医理论,咽为胃之关,喉为肺之门,外感之邪入肺易伤喉,饮食不当入胃易损于咽,咽喉为邪毒好浸久留之地。咽喉炎病因临床有内、外之分,外因多为感受风寒湿之邪,郁久化热或风热之邪,《温病条辨》曰"温邪上受,首先犯肺",咽喉居上,首当其冲感受温邪;内因多为素体阴虚,又嗜食辛辣煎炒,痰热蕴结,上灼咽喉或日久耗伤肺肾之阴,导致虚火上炎,灼伤津液成痰,痰热循经上扰咽喉,清道失利所致,正如《医宗金鉴》论喉痹的病理所说:“由肾阴久亏,相火上炎,消烁肺金,清肃之令不行”。目前,中西医往往很难治好慢性咽喉炎,咽喉炎在停药后易出现复发的情况。反复的发作不仅耽误了治疗的最佳时机,长期用药还会对患者的身体产生许多毒、副作用。
姚氏医家对三焦的认识,即三焦当为一个实质性的脏器,有其具体的生理、病理,诸多疾病迁延不愈与之有关。姚氏医家姚国美先生认为“三焦为人周身之油膜,内以包裹脏腑,外则达于皮里肉外,谓之腠理,其布于心肺间之脂膜,谓之上焦;肝、胆、脾、胃间之脂膜,谓之中焦;肾与膀胱、小肠、大肠间之脂膜,谓之下焦。以此统属之部位而分,故名之曰三焦。其根出于肾中,两肾之间,有油膜一条,贯于脊骨,是为焦原。”姚荷生教授认为三焦应该是一个有形的脏器,它的实质应该是人体内遍布胸腔、腹腔的一大网膜(包括胸膜、肋膜、膈膜、腹膜等等);所有脏腑都分居在它上、中、下三个地带,受着它的包裹与保卫。它与心包络相表里,它的外应组织为肌腠(腠理)。焦膜病的病机与其生理密不可分。
上焦焦膜与所在脏腑同居于上,共同主宣发气血津液。其病变多来自心肺,始则清阳之气为风、寒、湿、热所郁,其后有形之邪—水饮、痰浊流布胸胁,形成偏于气分的焦膜气郁,偏于水分的皮水、悬饮、水饮停聚于心下及心胸、柔痉等病变。
中焦焦膜与脾胃同居于中部,病多来自脾、胃,或脾胃不能运化水湿,水湿影响中焦焦膜,或水饮郁火而交结不解,水火互结于中。病虽在中焦焦膜,但发病亦可由中焦波及上焦和下焦。其病变诸如病机属性偏实的大结胸证,小结胸证,偏虚的痞证,虚实错杂的生姜泻心汤证、半夏泻心汤证、甘草泻心汤证等。
下焦焦膜与肝肾同居于下,其病变多受肝肾的影响,源自肾者,大多水气偏盛为患,源自肝者,瘀血较多,临床中,病变至此,病情较为深重,水与血交织为患,即“血不利则为水”,病因复杂,病机难辨。其病变诸如水气凌心的奔豚证,瘀浊互结的血臌、水臌等。
焦膜的病变特点:第一,呈持续性。因为焦膜为决渎之官,是体内津液敷布的通道,津液停聚,变成有形之邪,即水和饮,一旦病邪停留则疾病症状持续存在,即:邪之不去,病终不除。第二,临床表现为:闷、堵、痛、胀。闷即患者自觉从外向内的挤压感;堵即自觉上下不通之感;胀即自觉从内向外膨出感。因为三焦焦膜水道出焉,故一旦痰饮水湿阻滞其中,焦膜即受郁滞,就会出现胀、闷、堵等气机郁滞的临床症状,如心下痞,咽阻等。第三,反复发作,迁延不愈,邪属有形,难以排出。三焦焦膜病属腑病,阳病,是慢性病形成的一个主要途径,因不与外界相通,故有形之邪难以排出,变宿根,所以易反复发作。如自觉咽中有物有痰所阻,却难于咳咯排出。因为焦膜是水火运行之道路,道路受阻,津液停聚,煎熬成痰,郁而为湿,阻滞上焦焦膜。第四,易火邪为患。如少阳病提纲:“少阳之为病,口苦,咽干,目眩”,火为苦之味,火邪灼津,故见口苦,咽干。是因焦膜的相火易被痰饮水湿阻滞,相火被郁,即由生理的相火变为病理的相火。第五,多表现为既有表又有里的症状。焦膜是包括脏腑组织之外躯壳之内的腔囊,如胰腺炎,既出现腹痛,又可出现发热,焦膜病容易波及里外两层。
姚荷生教授的“三焦焦膜”理论,既契合中医传统理论,又对临床实践有非常重大的意义。三焦应该是人体内遍布胸腔、腹腔的一大网膜(包括胸膜、肋膜、膈膜、腹膜等)。它与心包络相表里,外应组织为肌腠(腠理)。通过相关文献资料记载与临床研究,复发性口腔溃疡和慢性咽喉炎的发生确实与“三焦焦膜”密切相关,特别是上焦焦膜与咽的关系很密切,口腔溃疡更是与上中下三焦关系均密切。从“三焦焦膜”论治慢性咽喉炎和复发性口腔溃疡是一条重要治疗途径,可以提高临床疗效。
慢性咽喉炎的中医证候类型:临床多以湿热痹阻上焦焦膜(以湿为重)为主,风湿热痹阻上焦焦膜(以风热为重)次之,气郁痰阻焦膜、寒风郁热上焦、痰湿痹阻焦膜、风火上犯上焦型更次之。临床复发性口腔溃疡的中医证候类型:湿热蕴毒证最为多见,占全部复发性口腔溃疡患者总数41.3%;其次热灼胸膈证,占全部复发性口腔溃疡患者总数32.6%,而最少的证型为热郁少阳证。
解剖上口腔与咽喉相连,也是细菌病毒聚集、潜伏最集中最多的地方;同时受消化道疾病的影响。慢性咽喉炎与复发性口腔溃疡均有相同的病因:暨各种原因造成的免疫力低下导致发病;均有最主要和最重要的病机:湿热(痰热、火热)蕴毒为患。以上联系为本发明组合物采取异病同治方法提供了理论基础。
目前中西医治疗慢性咽喉炎和复发性口腔溃疡的方法虽然不少,但均是单病种治疗,临床多只能缓解症状,难以从根本上进行康复治疗,西医治疗副作用大而且复发率较高。中药治疗理论体系不健全,作用机理研究不够深入,理论研究与临床应用亟待创新。
发明内容
针对上述存在的技术不足,本发明的目的是提供一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法,本发明中药组合物遵循“三焦焦膜”理论;采用异病同治的(同一组合物既能有效治疗复发性口腔溃疡又能很好的治疗慢性咽喉炎)方法;组合物具有清热解毒化湿、泻火、凉血、利咽,益气养阴生津,活血化瘀,化痰散结,敛疮生肌等功效;该中药组合物简便、价廉且无毒无副作用;该中药组合物服用方便,可使用现代工艺制备成多种剂型服用,此外还可批量生产,推广使用。
为解决上述技术问题,本发明采用如下技术方案:
本发明提供一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法,由下述重量/体积份数的各原料药制成:冬凌草10-50份、猫爪草6-15份、瓜蒌10-20份、薄荷6-15份、香附9-15份、麦冬10-20份、黄芪15-50份、白术9-15份、薏苡仁10-50份、姜黄9-15份、大黄6-15份、儿茶3-10份、熟地黄10-20份、黄柏6-15份、玄参9-20份、牡丹皮9-15份、姜黄6-15份、升麻9-15份、甘草9-20份。
所述各原料药的重量/体积份数优选为:冬凌草30份、猫爪草12份、瓜蒌12份、薄荷12份、香附12份、麦冬15份、黄芪30份、白术12份、薏苡仁30份、姜黄12份、大黄10份、儿茶5份、熟地黄15份、黄柏9份、玄参15份、牡丹皮12份、姜黄12份、升麻12份、甘草12份。
所述中药组合物 , 为按照现有工艺制成任何一种临床上可接受的制剂。
所述制剂为:口服液、煎剂、颗粒剂、丸剂或胶囊剂等。
所述的中药组合物煎剂的制备方法,其特征在于将所述重量份的中药组合物放入砂锅内,第一煎加 600—800 体积份的水,浸泡 20-40 分钟,先用武火煮沸后,再用文火煎25-35 分钟,取药液;第二煎加 500-700 体积份的水,先用武火煮沸后,再用文火煎 20-30分钟,取药液;合并两次的药液;所述的重量份的单位以 g 计,体积份的单位以 ml 计。把两煎药液混匀后分三次服,早、中、晚各服一次,温服。
所述的中药组合物颗粒剂的制备方法,其特征在于将所述重量份的中药组合物运用现有工艺的煎煮、浓缩、干燥、制粒等程序精制成颗粒,密封装袋。每袋12g,每次服 1 袋,每日服三次。
所述的中药组合物蜜丸的制备方法,其特征在于将所述重量份的中药组合物粉碎后,过100目或者120目筛制成极细药粉,灭菌再将药粉和蜜按1:1.2—1.8的重量比制成蜜丸。每丸3g、每次服12g,每日服三次。
所述的中药组合物胶囊剂的制备方法,其特征在于将所述重量份的中药组合物粉碎后,过100目或者120目筛制成极细药粉,将药粉装入空心胶囊,每粒 0.5g,每次服6粒,每日服3次。
本发明的有益效果:
具有清热解毒化湿、泻火、凉血、利咽,益气养阴生津,活血化瘀、化痰散结、敛疮生肌等功效。
该中药组合物简便、价廉且无毒、无副作用。
该中药组合物服用方便,可制备成口服液、汤剂、散剂、丸剂或胶囊剂等剂型进行服用,此外还可批量生产。
组方中各中药临床功效:
冬凌草:性味归经,味苦、甘,微寒,归肺、胃、肝经,具有清热解毒、活血止痛、消炎抑菌和抑制肿瘤等功效,用于治疗咽喉肿痛、瘕痞块、蛇虫咬伤以及食管癌、肺癌、肝癌等病症。现代临床试验证明,冬凌草通过调控癌细胞周期、改变生物膜通透性、诱导细胞凋亡等方面,对多种癌症均有显著疗效。此外,此药还可以用来治疗咽喉肿痛、症瘕痞块,蛇虫咬伤、口腔溃疡等疾病。现代研究其功效为:(一)抗肿瘤:冬凌草作为中医传统治疗肿瘤的药材,对多种癌症(食管癌、肝癌、肺癌等)均有显著疗效,经治疗可延长患者生命,稳定缩小瘤体,改善病患的生命质量。现代药理学证实,其除有显著的抗肿瘤功效,还可以减轻其他化疗药物引起的不良反应,协同提高治疗效果。Zhang 等研究冬凌草甲素对鼻咽癌的抗癌活性及其作用机制,发现冬凌草甲素能增强活性氧自由基的生成,抑制鼻咽癌细胞活力,降低细胞集落形成,提高鼻咽癌细胞凋亡率。(二)抑菌消炎:现代研究证实,冬凌草二萜类物质和有机酸成分对大肠杆菌、金黄色葡萄球菌、肺炎链球菌、伤寒杆菌等具有明显的抑制作用。这种抑菌机理是通过冬凌草提取物阻断微生物的生物膜形成和胞外多糖的合成,改变菌体生物膜的通透性。冬凌草甲素在炎症性疾病方面的研究表明,其抗炎作用主要与抑制NF-κB 信号通路有关,其可以减少包括白细胞介素-6( IL-6) 和肿瘤坏死因子-α(TNF-α) ,并抑制toll样受体4( TLR4) 表达的功能。(三)增强免疫力:冬凌草多糖通过促进淋巴细胞(包括T淋巴细胞和B淋巴细胞)的增殖,增强机体的免疫力。冬凌草甲素通过降低氧化应激反应、调节免疫球蛋白水平,增强机体免疫力。何荃等人研究发现冬凌草甲素能通过调节炎症相关因子的表达水平,进而调节抗炎和促炎因子失衡,抑制炎症通路蛋白NF-κB p65 和 MIP-2的表达,从而改善机体免疫紊乱。王一飞等[48]报道从冬凌草全草中分离得到冬凌草多糖对体液免疫和细胞免疫均有增强作用,采用MTT比色法可以观察其对刀豆素A 诱导的T淋巴细胞增殖以及脂多糖诱导的B淋巴细胞增殖均有促进作用。(四)抗氧化作用:裴保河报道冬凌草总黄酮对小鼠运动能力和抗氧化能力的影响,结果表明,冬凌草总黄酮可显著增强小鼠体内多种抗氧化酶的活性,延迟运动性疲劳的产生,作用机制为提高机体超氧化物歧化酶、过氧化氢酶的活性,并降低骨骼肌中丙二醛的含量,提高小鼠机体的抗氧化能力。
猫爪草:性味甘、辛,温。归肝、肺经,具化痰散结、解毒消肿之功,用于瘰疬痰核,疔疮肿毒,蛇虫咬伤。猫爪草具有多种药理作用抗结核、抗肿瘤、抗炎、免疫药理等作用。药理作用研究:1.1抗结核的功效;1.2 抗肿瘤作用:王爱武等运用MTT 和集落形成实验法发现,猫爪草皂苷及多糖对肉瘤S180、艾氏腹水瘤EAC 及人乳腺癌细胞株MCF-7 的生长和集落形成均有不同程度的影响,皂苷给药量与抑瘤率和集落形成明显的呈正相关关系。猫爪草皂苷也可以通过促进mfn2基因抑制人乳腺癌MCF-7细胞增殖及诱导其凋亡。也可能通过增加Ca2+浓度,调控相关基因表达,下调细胞线粒体膜电位而明显抑制人结肠癌LoVo细胞增殖和诱导其凋亡。猫爪草总皂苷对人肝HepG2、体外对人非小细胞肺癌A549细胞增殖和集落形成均有显著性的抑制作用,呈现较好的量效关系。 1.3 免疫活性作用:张振凌等采用环磷酰胺造模法制作免疫抑制小鼠模型,灌胃给药,观察猫爪草多糖及皂苷在影响小鼠非特异性免疫方面,明显提高正常小鼠腹腔巨噬细胞吞噬百分率和吞噬指数;在影响小鼠特异性体液免疫方面,显著促进溶血素的形成并提高外周中T 淋巴细胞数。猫爪草多糖对正常小鼠腹腔巨噬细胞吞噬功能的提高作用为最好,猫爪草多糖在体外能促进巨噬细胞T,B 淋巴细胞增殖活性及增加巨噬细胞吞噬能力。 1.4 抗菌作用:卞晓霞等采用牛津杯法探讨猫爪草提取物对常见的4种细菌的抑制作用,同时采用微量二倍稀释法测定其对不同供试菌株的最低抑菌浓度( MIC) 和最低杀菌浓( MBC)。实验表明猫爪草提取物对常见金黄色葡萄球菌、绿脓杆菌、大肠杆菌、痢疾杆菌四种细菌有较好的抑制作用,且抑菌活性随着药物浓度的增加而增强,猫爪草提取物具有较强的抗菌活性。 1.5 抗氧化作用:采用普鲁士蓝法测定猫爪草多糖的还原能力,水杨酸捕捉法测定猫爪草多对. OH 的清除能力,邻苯三酚自氧化法测定猫爪草多糖对O-2的清除能力。实验证明猫爪草多糖具有一定的还原能力,具有较强的清除. OH 和O-2的能力。 1.6 保肝作用:四氯化碳(CCl4) 是经典的小鼠急性肝损伤造毒物,其使肝细胞受损,血清丙氨酸氨基转移酶( ALT) 从受损的肝细胞溢出,使血清中ALT 升高,同时肝损伤时发生炎性病变,肝细胞肿胀。
香附:性味归经,味辛、微味苦、微甘,性平;归肝、脾、三焦经;功效作用,疏肝解郁,调经止痛,理气调中。主治疾病1、主要用于肝郁气滞胁痛、腹痛,月经不调,痛经,乳房胀痛,气滞腹痛等。2、西医诊为慢性胃炎、胃十二指肠溃疡、胆囊炎等。近年来国内外对香附的药理作用研究较多,证实具有抗炎、降血糖、抗血小板、保护神经系统、抗过敏反应等作用。抗炎作用, Seo 等提出 NO 和 O2-是诱导炎症性疾病发病的重要因素。通过采用γ-干扰素和脂多糖刺激小鼠巨噬细胞 RAW 264.7 细胞产生 NO,巴豆油脂刺激小鼠巨噬细胞 RAW264.7 细胞产生 O2-,发现香附根茎甲醇提取物能显著抑制 NO、O2-产生。采用 Western和 Northern 凝胶电·473·齐鲁事·Qilu Pharmaceutical Affairs 2012 Vol. 31,No.8泳法发现其通过抑制诱生型一氧化氮合酶( iNOS) mRNA 和蛋白表达减少NO 的生成。Tsoyi 等采用脂多糖活化 RAW 264.7 细胞促进其 iN- OS 表达和 NO 的生成,发现香附乙醇提取物能诱导对 iNOS 发挥重要抑制作用的血红素加氧酶-1的产生且呈浓度依赖性,其中诺卡酮和瓦伦烯作用显著。此外发现香附乙醇提取物对脂多糖活化的小鼠巨噬细胞中高迁移率族蛋白 1 ( HMGB1) 产生强烈的抑制作用,从而提高由于盲肠结扎穿孔术引发败血症的小鼠的生存率。
牡丹皮:性味归经,苦寒、归心、肝、肾经;清热凉血,活血化瘀。功能主治清热,凉血,活血消瘀。治热入血分,发斑,惊痫,吐、衄、便血,骨蒸劳热,经闭,症瘕,痈疡,扑损。现代研究其有非常显著的抗菌消炎的功效。其化学成分主要包括苯乙酮类、萜类及其苷类、有机酸类以及其他类成分,具有抗炎、调节免疫功能、保护心血管等作用。抗癌的功效:Li等通过体内、体外实验研究发现:牡牡丹皮所含的主要活性成分牡丹皮酚对鼠源性MFC和人源性SGC-790胃癌细胞均有显著的抑制作用,表明牡丹皮酚具有抗胃癌的作用;进一步研究发现其作用机制可能与下调瘤细胞Bcl-2基因表达和上调Bax基因表达有关。
黄柏:性味归经,味苦,性寒;归肾、膀胱、大肠经;清热燥湿,泻火解毒,除骨蒸。主治疾病:湿热带下,热淋涩痛:本品苦寒沉降,长于清下焦湿热。现在药理研究认为,它有抗菌、抗心律失常、降压、调节免疫、抑制免疫的作用,还有降尿酸的作用。现代研究证明:1、抗菌作用,黄柏煎剂水浸出液或乙醇浸出液对化脓性细菌抑菌作用强,尤其对金黄色葡萄球菌,表皮球菌,化脓性链球菌等阳性球菌有较强的抑菌效果。2、抗炎:黄柏水浸出液对二甲苯所致的鼠肿胀有明显的抗炎作用,对健康豚鼠做化腐生肌发现黄柏冷敷剂对金黄色葡萄球菌感染的破损皮肤有明显的抗炎作用。3、抗病毒:蔡宝昌等选择 32种天然药物的水提取液对接种了单纯疱疹病毒而引发疱疹的小鼠给药与阿昔洛韦(已禁止使用编者注)对照组及空白对照组比较发现黄柏给药组可延缓疱疹症状发作时间和扩散时间,延长小鼠生存时间并显著降低小鼠的死率。4、免疫抑制作用:黄柏具有抑制细胞免疫反应的作用,其活性物质为黄柏碱和木兰花碱,它们均可抑制小鼠的局部移植组织的宿主反应,也抑制苦基氯诱导的迟发型超敏反应小鼠的诱导期。5、抗溃疡作用:胃黏膜产生大量活性氧是捆束水浸应激性溃疡发生的原因之一,而除去小檗碱的黄柏组分对小鼠捆束水浸应激性胃溃疡有抑制作用。
瓜蒌:性味归经,味甘、性寒,归属肺、胃、大肠经。全瓜蒌能够清热化痰、宽胸散结、润肠通便;第一,呼吸系统的疾病,肺热咳嗽,特别是大块的痰,比较黏稠,不容易咳出,像热痰、黄痰,效果比较好,有一个化痰的作用。第二,对于治疗胸痛、心痛,瓜蒌我们比较常用。第三,治疗痈,就是脓肿,包括乳腺的脓肿、肺脓肿、急性的阑尾炎,叫肠痈,这种肿痛效果比较好。第四,它有润肠通便的作用,所以对于大便干结、便秘的人也常用瓜蒌。瓜蒌中含有丰富的氨基酸,而且里面还含有一些天门冬氨酸,这两种物质能够祛痰,并且还可以增强免疫力,它可以有效抑制炎症。瓜蒌水煎剂中有能够抑制细菌的物质,而且瓜蒌煮出来的水,还可以治疗皮肤真菌疾病。瓜蒌可以起到扩张冠状动脉的作用,它可以有效防止血液堵塞,并且能够增强心肌功能。瓜蒌酸可以防止血小板凝聚,能够预防血液黏稠度过高的症状。其行气开郁,身体气血运行不畅,经常喘息,咳嗽的人就可以吃一些瓜蒌。瓜蒌可以促进全身的血液循环,而且还可以起到补气的功效。
黄芪:性味归经,甘,微温,归于脾、肺两经,具有补气升阳、益卫固表、利尿消肿、托毒生肌的功效。在临床上,黄芪主要用于脾胃气虚以及中气下陷的病症;可以用于肺气虚以及表虚自汗的病症;也可以用于气虚水肿以及内热消渴等病症。能显著增强机体免疫力。1、对免疫功能的影响:黄芪对正常机体的抗体生成功能有明显促进作用,可提高小鼠的血清igG含量,黄芪水提液可使肝炎患者的总补体和各种补体含量升高,除多糖外,蛋白质大分子、氨基酸、生物碱及苷类均有促进抗体生成作用。 2、抗菌抗病毒作用:黄芪对多种细菌有抑制作用,如炭疽杆菌、肺炎双球菌等,并可抵制某些病毒的感染,如可保护小鼠对Ⅰ型副流感病毒感染,黄芪多糖对结核分枝杆菌也有明显的拮抗作用。3、对机体抗应激能力的影响:黄芪能明显提高机体的抗应激能力,实验研究显示黄芪能增强小鼠抗疲劳、耐低温、抗缺氧、抗辐射等能力。
薄荷:性味归经,性味辛凉,归肺经和肝经。功效与作用:薄荷主要有疏散风热、解毒透疹、清利咽喉、疏肝理气的功效,具体如下:1、薄荷的疏散风热的功效主要用于治疗风热感冒证,临床上表现为发烧、怕冷、嗓子痛、头痛、咳嗽、咳吐黄痰或者咳痰不爽、大便偏干等感冒症状;2、薄荷有清利头目的功效,用于治疗外感风热或者外感风寒入里化热引起的咽喉疼痛、头痛等症状;3、薄荷有解毒透疹的功效,对于麻疹疹出不畅,用薄荷可以使麻疹迅速透发出来,缩短病程;4、薄荷有通鼻窍的功效,可用于治疗感冒引起的鼻塞、流鼻涕或者过敏引起的鼻塞、流鼻涕;5、薄荷有疏肝解郁、理气的功效,对于肝气不舒引起的胁肋疼痛、心情不畅、失眠多梦、郁郁寡欢等症状可以起到很好的治疗作用。6、薄荷化学成分主要包括薄荷醇和薄荷酮等挥发性成分与甾体、黄酮、三萜等非挥发性成分。具有抗炎、抗真菌、抗肿瘤、抗氧化、抗辐射等多种药理作用。现代研究其有非常显著的抗菌消炎的功效,口腔溃疡常使用。
熟地黄:性味归经,性味甘、温,入肾经,主要作用是滋补肾阴。熟地黄具有良好的滋补阴血、益精髓之功,历代本草对此都有记载。《药品化义》言:“熟地,借酒蒸熟,味苦化甘,性凉变温,专人肝脏补血。因肝苦急,用甘缓之,兼主温胆,能益心血,更补肾水。凡内伤不足,苦志劳神,忧患伤血,纵欲耗精,调经胎产,皆宜用此。安五脏,和血脉润肌肤,养心神,宁魂魄,滋补真阴,封填骨髓,为圣药也。”熟地黄作为临床常用中药,不仅常用于临床方剂配伍,应用单味熟地黄活性也广泛,其水提液、醇提液和主要化学成分具有多种药理作用。目前研究主要集中在对血液系统、神经系统、免疫系统的影响,以及抗肿瘤、抗衰老、促进内皮细胞增殖等方面。现代研究,熟地黄所含的地黄多糖具有明显的免疫抑瘤活性,还有显著的强心、利尿、保肝、降血糖、抗增生、抗渗出、抗炎、抗真菌、抗放射等作用。
玄参:性味归经,味甘、苦、咸,性微寒;归肺、胃、肾经;清热凉血,泻火解毒,滋阴。主治疾病:温邪入营,内陷心包,温毒发斑:本品咸寒入血分。现代研究,
1、抗菌作用:本品对多种致病性及非致病性真菌具有抑制作用。在试管内玄参对须疮癣菌、絮状表皮癣菌及羊毛状小芽孢癣菌有抑制作用。玄参水浸剂 (1 : 3 ) 在试管内对奥杜盎小芽孢癣菌也有抑制作用。以大肠杆菌、金黄色葡萄球菌和铜绿假单胞菌为目标菌,采用滤纸片法测定抑菌圈及测定药物的MIC 法研究了玄参化学成分的抗菌作用,实验表明:哈帕苷,桃叶珊瑚苷, eurostoside,哈帕俄苷,scrokoelziside A ,Scrok oelzisid B对大肠杆菌、金黄色葡萄球菌、铜绿假单胞菌均具有抗菌活性,这些化合物可能是玄参抗菌作用的物质基础。2、抗炎镇痛作用:实验证明苯维生素C普类成分的抗氧化作用与玄参的抗炎活性有密切关系,苯维生素C苷类抗氧活性明显比环烯醚砧类强。玄参色素抗炎镇痛实验表明:玄参中色素类提取物对二甲苯致小鼠耳廓肿胀对冰醋酸致腹腔毛细血管通透性增高均有明显地抑制用,提高热板致痛小鼠的痛闭值及减少冰醋酸刺激致痛小鼠的扭体次数。3、免疫增强活性:毛小平等研究了玄参能升高在生理条件及环磷酞胺所致免疫功能抑制条件下的白细胞数和胸腺指数。谢丽华等报道了哈帕醋苷皮下注射能使阴虚小鼠抑制的免疫功能恢复,发现哈帕醋苷和哈帕苷都能促进阴虚小鼠体外脾淋巴细胞增殖。 4、抗氧化作用:刘质净等采用Folin 一Ciocalteu 方法测定玄参不同提取物的总多酚含量,并通过DPPH抗氧化活性体外评价体系测定玄参不同提取物的抗氧化活性、清除自由基的能力。结果表明40%乙醇提取物的总多酚含量最高,而20%乙醇提取物具有最好的清除DPPH自由基的能力。证明玄参中多酚类化合物具有较好的体外抗氧化活性。
麦冬:性味归经,味甘,微苦,微寒,归心、肺、胃经,主要的功效是养阴生津、润肺止咳。麦冬可以有效提高身体免疫力,对于多种细菌都具有一定的抑制作用,而且还具有扩张血管,降低心律失常的功效。可以有效地降低体内的血糖,减少患病的可能,麦冬还具有润肺止咳的功效,对于心脏、肺部,还有胃部都具有很好的调节作用,而且还可以用来治疗冠心病,以及萎缩性胃炎等疾病。麦冬富含丰富的纤维素,可以有效促进肠胃蠕动,增进新陈代谢,可以改善胃肠干燥导致的便秘。
甘草:性味归经,味甘,归心经、肺经、脾经、胃经;它的功效主要是补脾益肺益气、清热解毒、祛痰止咳、缓急止痛、调和诸药。1、清热解毒:甘草可以泻心火,有清热解毒的作用,现代医药学已经证实,甘草有较好的解毒功能,还能抑制胃酸分泌,适量食用甘草,对胃肠道溃疡病也有一定的预防和改善作用;2、镇咳祛痰:甘草口服以后能作用于发炎的咽部黏膜上,缓和炎性刺激、起到镇咳作用,同时甘草还能促进咽部和支气管黏膜分泌黏液,使痰容易咳出;3、甘草可以补脾益气,甘草色黄味甘,气温益气,是补脾益气的常用药物,经常和党参、白术等补脾益气的药物一起使用,用于治疗多种气虚证,比如心气虚、心悸、脾胃虚弱等症状;能增强机体免疫力。4、调节药性:甘草独具甘味,有缓和其他药味性能的作用,所以常用在复方中,能起到协调其他药物性味的功能,在各类药方中甘草能使各种药物互相和谐,所以前人认为甘草能调和百药,是不同性质的药物协调一致发挥作用。
儿茶:性味归经,味苦、涩,性凉;归心、肺经;功效活血疗伤,止血生肌,收湿敛疮,清肺化痰。主治疾病:1、跌打伤痛,出血:本品性涩,既能活血散瘀,又能止血生肌,收湿敛疮,清肺化痰。现代研究其具有:1.清热化痰:由于儿茶性凉,所以可以服用儿茶,可以起到清热化痰的作用,对于痰热咳嗽、烦热消渴等症状都有很好的治疗效果。2.止血定痛:该药具有活血散瘀、疗伤止痛的功效,如皮肤因跌打损伤导致出现肿痛症状,或出现血症状,可用儿茶研末外敷,如与龙骨、血竭、白等中药研末外敷,效果会更好。3.收湿敛疮:儿茶收敛得很好,所以皮肤上出现疮疡,很难痊愈时,可将儿茶粉末敷在患处,可以起到很好地去腐生肌的作用。皮肤上出现湿疹的时候,也可以用这种药物来缓解。4.具有杀菌、抗菌作用:儿茶有很好的杀菌抑菌作用,尤其是对金黄色葡萄球菌、伤寒杆菌等细菌,具有很好的杀灭和抑制作用,对由真菌引起的皮肤感染也有治疗作用,所以儿茶对脚气有很好的治疗作用。5.利水消肿:由于儿茶具有很好的利水作用,所以身体有浮肿症状,或者由于肝硬化等疾病严重出现腹水,应用这种药物也能起到很好的治疗效果。6.胃溃疡的预防:实验表明,儿茶能促进肠胃蠕动,还能使肠管张力增高,适量服用儿茶可以很好地预防胃溃疡。
大黄:性味归经,味苦、寒,归脾、胃、大肠、肝、心经,主要功效是泻下攻积、清热泻火、解毒、活血祛瘀、清泻湿热,临床用于以下几方面:第一、肠道积滞、大便闭结,大黄性味苦寒、沉降,有较好的泻下作用,是治疗积滞便秘的主要药物,尤其适应于热结便秘,此外对于热痢初起、肠道湿热积滞不化的,也可以用大黄通便,去除湿热积滞。第二、用于血热妄行的吐血、鼻衄,也就是鼻子出血,牙龈出血,以及火邪上炎导致的目赤、咽痛、牙龈肿痛等。第三、用于热毒疮疡以及烧伤,因为大黄有清热解毒和通便的作用,可以使热毒下泻。第四、用于瘀血症,比如妇女的瘀血闭经、产后恶露不下、症瘕积聚及跌打损伤等,大黄能活血祛瘀,是治疗瘀血症的常用药,无论新瘀血还是陈旧瘀血都可以使用。第五、大黄可以用于黄疸、淋病等湿热证,因为其性味苦寒、泄降,能清泻湿热。生大黄泻下力量较强,久煎后泻下力量减弱,酒制大黄泻下力量较弱,活血作用比较好,大黄炭多用于出血症。现代研究证明:1.大黄具有很强的抗感染作用、抗衰老抗氧化作用、能够调节免疫、抗炎、解热作用、抗病原微生物作用、降血脂、止血作用、抗胃及十二指肠溃疡、促进胰液分泌、抑制胰酶活性、利胆、保肝、泻下作用。2.大黄有抗感染作用,对多种革兰氏阳性和阴性细菌均有抑制作用,其中最敏感的为葡萄球菌和链球菌,其次为白喉杆菌、伤寒和副伤寒杆菌、肺炎双球菌、痢疾杆菌等。3.大黄能增加肠蠕动,抑制肠内水分吸收,促进排便。4.还有止血、保肝、降压、降低血清胆固醇等作用。5.生大黄能够泻热通肠,逐瘀通经,凉血解毒。用于瘀血经闭,跌打损伤,湿热黄疸,血热吐衄,湿热便秘,积滞腹痛,肠痈腹痛,泻痢不爽,目赤,咽肿,痈肿疔疮,外治水火烫伤;上消化道出血。大黄炭凉血化瘀止血。用于血热有瘀出血者。
薏苡仁:性味归经,味甘、淡,性凉;归脾、胃、肺经;功效作用利水渗透湿,健脾止泻,除痹,排脓,解毒散结。主治疾病,主治水肿,脚气,小便不利,脾虚泄泻,湿痹拘挛,肺痈,肠痈;赘疣,癌肿。现代研究证明:防癌抗癌其所含的硒元素能有效抑制癌细胞的繁殖,可用于皮肤癌、子宫颈癌的辅助治疗。薏苡仁含有脂肪酸及酯类、多糖、黄酮、三萜、生物碱、甾醇、内酰胺、淀粉等多种化合物,在薏苡仁治疗疾病时各自发挥不同效果,共同达到治疗目的。现代研究发现薏苡仁除了在传统中药理论中有良好的祛湿利水效果外,也能治疗多种癌症、高血压、高血脂、脂肪肝、类风湿性关节炎等疾病,还能增强免疫、调节肠道菌群,也可作为药膳辅助疾病的治疗,而且临床不良反应少,用药更为安全。
姜黄:性味归经:味辛、苦,性寒;归肝、胆、心经;功效活血行气,通经止痛。主治疾病:气滞血瘀痛证,可以用于治疗气滞血瘀导致的胸胁刺痛、胸痹、心痛等病症。姜黄辛温而味苦,能外散风寒湿邪、内行气血、通经止痛,可以治疗痛经、闭经、症瘕积聚等症状。也可治疗风湿痹痛、四肢酸重、肌肤麻木,尤为治颈肩腰腿疼常用药。此外,还可以治疗跌扑肿痛、痈肿疔疮等。它有破气行血的功用。药理作用:1、抗菌功效,姜黄素能作用于金黄色葡萄球菌,水煎液可起到抗菌作用,能够达到抑制皮肤真菌的目的。2、降压功能,通过动物实验研究得知,醇提物对麻醉犬可取得良好的降压效果。3、利胆功效,水煎液具备利胆功效,其中所含有的黄色素可起到消除阻塞性黄疸、收缩胆囊的功能。
现代研究有以下功效:1、抗肿瘤作用:用鼠Dalton氏淋巴腹水瘤细胞进行组织培养及在体实验,姜黄醇提物能抑制癌细胞生长。在0.4mg/ml时能抑制中国仓鼠卵巢细胞生长,并对淋巴细胞和Dalton氏淋巴细胞具有细胞毒性作用,并能减少动物肿瘤的生长,其活性成分主要是姜黄素。2、抗炎作用:姜黄素能对抗角义菜胶诱发的大鼠脚趾肿胀,在30mg/kg范围内有剂量依赖性,而剂量在60mg/kg 时,则抑制这种抗炎作用。姜黄素钠可逆地抑制尼古丁、乙酰胆碱、5-羟色胺、氯化钡及组胺诱发的离体豚鼠回肠收缩,类似于非固醇类抗炎药。3,抗病原微生物作用:体外试验,姜黄素百分之一浓度时,对细球菌(Micrococuspyogenesvar. Aureus)有抑制作用。挥发油有强力抗真菌作用。姜黄能延长接种病毒小鼠的生存时间。4、对心血管系统的影响:姜黄素静脉注射对血压无明显影响,对肾上腺素、组胺和乙酰胆碱引起的血压亦无明显影响。用姜黄素灌胃能对抗垂体后叶素静脉注射引起的大鼠心电图S-T、T波变化,灌胃还能增加小鼠心肌营养性血流量。
白术:性味归经,味甘苦,性温,归脾、肺经。益气健脾、燥湿利水、固表止汗、安胎。常用于脾气不足所见的食少便溏、气虚乏力等症。白术多与人参、炙甘草、茯苓同用,如四君子汤。白术具有燥湿利水的作用,多用于痰湿中阻所见的胸闷、胸疲等症;也用于治疗风寒湿痹,主治积表,如麻黄加术汤;白术还具有固表止汗的作用,多用于表虚、自汗、盗汗等;白术具有安胎的作用,可促进水谷运化与养胎,多用于胎动不安,麸炒白术可增强补气、健脾、止泻的功效。现代研究具有以下功效1.抗溃疡,白术这味中药材具有抗溃疡的功效,它所含有的丙酮提取物可以抑制胃黏膜损伤,还能够抑制胃酸分泌,让胃液的酸度降低,并且减少胃蛋白酶的排出量,达到预防溃疡的目的。2.增强身体造血功能,白术还能够增强我们身体的造血功能,它可以促进红细胞生成,对于改善贫血症状有很好的帮助。3.降血糖,白术还具有一定的降血糖功效,它可以让我们身体当中的葡萄糖更好地被氧化和利用,从而达到降低血糖的目的,适合血糖高和糖尿病的患者服用。4.抗氧化,白术还具有非常好的抗氧化功效。白术进入了体内之后,能够很好地抑制脂质过氧化,降低这种过氧化物的含量,避免有害的物质对身体的组织细胞和功能造成破坏。5.抗肿瘤,因为白术对肿瘤细胞有细胞毒作用,所以它能够有效地降低肿瘤细胞的增殖率,减少它的危害性,从而达到抗肿瘤的目的。6.保肝护肝,白术还具有保肝护肝的功效,服用了白术之后,能够有效地减轻肝糖原减少以及肝细胞变性坏死的情况,同时也可以促进肝细胞生长,使丙谷转氨酶下降。
升麻:性味归经,味辛、微甘,性微寒;归肺、脾、胃、大肠经;解表透疹,清热解毒,升举阳气。主治疾病:1、外感表证:本品辛甘微寒,性能升散,有发表退热之功效。现代常用于时气疫疠,头痛寒热,喉痛,口疮,斑疹不透;中气下陷,久泻久痢,脱肛,妇女崩漏,子宫下坠;痈肿疮毒等症的治疗。现代药理学研究发现,其具有抗炎、抗病毒、调节胃肠动力、抗肿瘤、抗抑郁、抗骨质疏松、抗氧化等作用。作为升阳药,升麻可调节胃肠动力,然而其主要药理活性成分及机制还需进一步阐明。升麻主要通过调控炎症因子分泌而发挥抗炎作用,也可通过减少DNA合成发挥抗病毒作用,但其品种选择、剂量确定及具体作用靶目标仍需进行深入系统研究。近年来,升麻的抗肿瘤及镇痛作用备受关注,其阻滞信号通路、抑制细胞增殖、调控抑癌基因等多维抗癌活性已得到证实,但其研究多停留在细胞水平,今后,需进行更深层次的研究。
乌梅:乌梅:味酸、涩,性平,归肝、脾、肺、大肠经,临床上应用范围广,多用于治疗肺虚久咳、久泻久痢、蛔厥腹痛以及消渴病等。现代研究发现,乌梅具有抑菌、镇咳、镇静、抗病毒、抗肿瘤等作用。现将乌梅的药理作用及其临床应用的研究进展进行总结归纳如下:乌梅化学成分丰富,主要包括有机酸、萜类、甾醇、生物碱、脂类、黄酮类及挥发性成分等,多种多样的化学成分是乌梅临床应用广泛的重要药理基础。1、抑菌作用,乌梅的抑菌作用亦主要得益于其有机酸成分,乌梅有机酸提取液具有广谱抗菌作用,对枯草杆菌、金黄色葡萄球菌、大肠杆菌和四联球菌等具有明显的抑制作用。徐俊峰等[4]通过探讨乌梅肉水提取液对口腔变形链球菌的作用,发现乌梅水提取液能有效抑制变形链球菌及其牙体细菌生物膜的形成,因此对变形链球菌这一最主要的致龋菌具有有效的杀灭作用,既能有效防治龋齿,将乌梅用于治疗口腔疾病是中医药临床的重要创新。 2、调节肠道菌群,研究发现,乌梅对肠道菌群的调节作用主要体现在改善有益菌和有害菌的比例及调节肠道菌群的丰度上。李逸飞等构建广谱抗生素诱导的小鼠肠道菌群紊乱模型,通过16SrRNA 基因测序对比乌梅干预前后小鼠的肠道菌群情况,证明乌梅可以通过对肠道菌群的调节改变肠道微生态环境,治愈复杂的消化系统疾病。3、抗氧化应激作用。4、抗肿瘤作用,乌梅治疗恶性肿瘤主要通过促进肿瘤细胞凋亡、减少肿瘤坏死因子α的分泌、抑制相关信号通路、减少致癌基因表达等实现。5、抗变态反应作用。6、止渴作用,乌梅的止渴机制主要是通过刺激唾液腺分泌唾液来实现。因其味酸,结合中医性味理论认为,乌梅功能养阴生津,临床上多用于治疗以阴虚内热为基本病机,以口渴、咽干等为主要表现的诸多疾病。7、促进细胞修复、保护神经作用,研究发现,乌梅对动物炎性肠黏膜上皮细胞有明显的修复作用,其主要表现为细胞凋亡形态的改善和细胞凋亡数量的减少。王春玲等研究发现,乌梅总黄酮能降低 Bax、半胱氨酸蛋白酶-3 (Caspase-3)水平并升高 Bcl-2/Bax 比值,从而抑制 1- 甲基 -4 苯基吡啶离子(MPP+ )诱导的细胞凋亡。8、五官科方面的运用,乌梅性平味酸,有敛肺涩肠、蚀恶肉、散结、化痔消息肉之功。因而在息肉等黏膜增生性病变中加用乌梅,往往疗效显著。周昕等将 90 例慢性鼻窦炎伴鼻息肉患者随机分为对照组和治疗组,治疗组给予济生乌梅片联合生理盐水喷鼻治疗,对照组给予布地奈德喷鼻剂联合淀粉片治疗,研究发现治疗组的疗效显著,能明显增强鼻腔通气作用,促进鼻黏膜修复,其治疗效果与常规激素治疗差别不大,且不良反应更(P<0.05),值得临床推广。
组合物配伍功效增益:
本组合物冬凌草清热解毒、活血化瘀止痛、消炎抑菌和抑制肿瘤主治口腔、咽喉疾病,既治疗咽喉疼痛,又清脾胃上炎至口腔溃疡之火为君药。玄参清热凉血,滋阴降火,解毒散结;姜黄即入气分解表祛风、寒、湿邪,又入血分活血化瘀止痛、消炎抑菌和抑制肿瘤;猫爪草清热解毒、化痰散结;3药共为臣药。基本体现了本组合物清热解毒泻火、利湿、凉血、利咽,滋阴,化瘀祛痰散结的主治功效;且4味药均有非常显著的抗菌消炎、抗肿瘤、提高机体免疫力等功效。其余药配合起佐使药的功效。
方中猫爪草易射干、薏苡仁易通草、瓜蒌皮易枇杷叶、薄荷易淡豆豉取上焦宣痹汤之意。具有清热祛湿(祛除体内湿热邪气)、宣痹通络的功效;有利湿化痰、调畅上焦气机的作用,加薏苡仁可使湿热从小便排泄而出。可以用于痰热蕴肺、肺失宣肃所致的咳嗽喘息、咳痰黏稠、色黄痰吐不利、胸膈满闷等症状;临床对慢性咽喉炎的治疗有非常好的疗效。配伍“风药”升麻、薄荷发挥升散上焦火毒之功效,起引经药的(佐使药)作用,助君药冬凌草清热解毒、疏散上焦火毒。麦冬养肺胃生津止渴、乌梅养阴生津、牡丹皮清热凉血共佐助玄参清热凉血解毒散结;大黄清火解毒利湿热、活血祛瘀凉血,儿茶活血祛瘀生肌,共佐助姜黄活血化瘀,加速口腔、咽喉部溃疡创面的愈合。瓜蒌开胸顺气,通调上焦水津通道,同时与薏苡仁一起佐助猫爪草发挥解毒、行气化痰散结消肿之功效。
本发明认为:慢性咽喉炎和复发性口腔溃疡中焦原本多虚,在气虚的基础上进一步发展为气虚湿阻、痰湿蕴热,最终导致中焦虚实夹杂,寒热错杂,痰瘀互阻,肝脾、脾胃、肝胃等功能失调。黄芪、白术健脾益气除湿,加薏苡仁健脾除湿利尿,其还能增强免疫、调节肠道菌群作用;乌梅酸甘养阴、与麦冬一起养肝胃之阴,乌梅有非常显著的调节消化道菌群的功效;香附宣中下焦气机,薄荷协助其条畅肝脾、肝胃气机;姜黄疏肝行气活血,姜黄有温补脾胃的功效,因为从中医食疗的角度讲,姜黄性味偏温热,因此对于脾胃虚寒所导致的食欲缺乏、恶心、呕吐、腹痛、腹胀、腹泻,通过温补脾胃的阳气,祛除脾胃的寒气,有增进食欲、促进消化的功效;大黄涤荡肠胃湿热,使邪毒从大便排泄而出,甘草、白术、薏苡仁均有利尿作用,共奏中下焦水津通道顺畅。相关药物在组合物中起佐助药的功效。甘草在本配方中主要起清热解毒和调和诸药的作用。
慢性咽喉炎和复发性口腔溃疡临床下焦多虚火:熟地黄补肾阴,牡丹皮、玄参养肺肾之阴、解血分之毒;黄柏清下焦虑火,引火归原。熟地黄与黄柏配伍,黄柏苦寒坚肾阴而清肾热,熟地黄甘温滋肾阴而壮肾水,合用壮肾水制相火,用于治疗阴虚火旺,咽干口燥、潮热盗汗等病症。相关药物在组合物中起佐使药的功效。
本组合物选药组方特色增益:
本组合物“排兵布阵”鲜明地体现了“有病治病、无病防变”和“治未病”的思想。本组合物在有效的治疗复发性口腔溃疡和慢性咽喉炎的基础上,充分地考虑到疾病的演变规律,前瞻性运用了大量的兼抗肿瘤功效的药物,充分体现“治未病”思想。
冬凌草作为君药的特殊作用:冬凌草苦、微寒,有清热解毒、活血消肿止痛,化瘀散结的功效,在本组合物中发挥提纲挈领的作用。现代研究发现,冬凌草单药不但治疗慢性咽喉炎有非常显著的功效,而且对复发性口腔溃疡也有非常显著的治疗作用。
姜黄作为臣药的特色作用:姜黄助君药冬凌草活血祛瘀,其辛温可以适当对抗冬凌草的寒性,更加能促进血液的循环;姜黄除具有促进口腔、咽喉溃疡面的恢复,同时具有非常显著的抗消化道肿瘤的功效。
猫爪草作为臣药的特色作用:猫爪草协助君药冬凌草清热解毒,同时弥补其化痰散结功效之不足;猫爪草性味甘、辛,温,辛温可以适当对抗瓜蒌等的寒性,更加能促进痰结合肿瘤的消散;猫爪草不但有非常显著的抗口腔及咽喉病毒、细菌的功效,而且具有非常显著的抗消化道肿瘤的功效。同时本配方猫爪草伍香附,加强了疏肝行气解郁、化痰散结之功效。川北地区气候独特,常发鼻、咽喉相关疾病,猫爪草具有化痰散结之效,为耳鼻咽喉科常用的中草药。猫爪草具有抗炎、促进增生的淋巴滤泡变小的作用,对慢性咽炎的治疗多收佳效。有研究以咽部体征作为疗效判定指标观察了猫爪草对慢性咽炎的临床疗效,结果显示,服用单味中草药猫爪草6g,连用30d,实验组改善率显著高于安慰剂组,且未见不良反应。
玄参作为臣药的特色作用:玄参协助君药冬凌草清热解毒、化瘀凉血消肿散结,同时弥补冬凌草解毒凉血散结滋阴功效之不足。其归肺、胃、肾经;清热凉血,泻火解毒,滋阴、软坚散结。标本兼治,肺胃肾和上中下三焦兼顾,且有非常显著的抗菌消炎功效。
本组合物乌梅使用的特色:乌梅有非常显著的抗口腔病菌、抗消化道肿瘤等功效。乌梅酸甘化阴,生津止渴,敛肺止咳,能生津很好的治疗咽喉干咳疼痛,又能收敛肺气治疗久咳;乌梅在五官科的应用更是特色,徐俊峰等通过探讨乌梅肉水提取液对口腔变形链球菌的作用,发现乌梅水提取液能有效抑制变形链球菌及其牙体细菌生物膜的形成,因此对变形链球菌这一最主要的致龋菌具有有效的杀灭作用,既能有效防治龋齿,将乌梅用于治疗口腔疾病是中医药临床的重要创新。
本组合物清热解毒特色:冬凌草清热解毒活血化瘀,瓜蒌、猫爪草清热解毒化痰散结,升麻清热解毒散火,玄参清热解毒凉血散结,大黄清热解毒通腑祛湿热,黄柏清热解毒退虚热。
祛痰特色:黄芪、甘草、白术益气健脾化痰,薏苡仁健脾除湿化痰,猫爪草解毒化痰散结、瓜蒌清热解毒化痰散结,儿茶清热止咳化痰,瓜蒌、香附行气化痰。
借鉴“三焦焦膜”理论,三焦同治,异病同治;治疗方式方法的创新。
本组方不论是补益的黄芪、白术、甘草,还是解毒活血的大黄、冬凌草,行气活血的姜黄,利湿的薏苡仁、行气宽胸的瓜蒌,凉血解毒的玄参、牡丹皮等均有显著的提升机体免疫力的功效。黄芪配姜黄增强益气活血的功效,同时能减轻姜黄破血的副作用。
本组方不论是解毒活血的大黄、冬凌草,行气活血的姜黄,还在疏散风热的薄荷,凉血解毒的玄参、牡丹皮等均有显著的抗菌的功效、能有效治疗口腔、咽喉常见病毒、细菌和真菌等感染。同时本组合物各药还有非常显著的抗肿瘤的功效,能预防阻止该病向癌病发展。
本组方重视活血药的使用。近年来的研究发现,RAU 的结缔组织中呈局灶性的白细胞碎屑性血管炎,具有Arthus 型损害,这提示 RAU与变应性血管炎有关,变应性血管炎也称过敏性血管炎,白细胞破碎性血管炎,变应性脉管其特征是小血管毛细血管受累,血壁有中性粒细胞浸润和粒细胞破碎,血管壁坏死,并有纤维蛋白物质沉积,临床表现则以皮肤和黏膜溃疡病损为主。中医辨证认为,变应性血管炎的病机在于气滞血瘀,阻滞脉道,血流不通而渗于脉外。瘀滞日久生则新血不生,或湿热日重,热毒阻络,灼伤脉络,迫血妄行,因而使黏膜和皮肤失于濡养。因此,我们从中医辨证施治出发,以清热利湿,活血解毒为主要的治疗方法。冬凌草清热解毒活血化瘀止痛,姜黄活血行气解郁,牡丹皮活血凉血祛瘀,玄参活血凉血解毒散结,大黄解毒活血祛瘀通腑,儿茶活血祛瘀生肌,共奏加速口腔、咽喉血液循环,及时排出毒素、加速溃疡创面的修复愈合。
具体实施方式
下面将结合本发明实施例对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施条例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法,由以下组分的原料制备而成:冬凌草30份、猫爪草12份、瓜蒌12份、薄荷12份、香附12份、麦冬15份、黄芪30份、白术12份、薏苡仁30份、姜黄12份、大黄10份、儿茶5份、熟地黄15份、黄柏9份、玄参15份、牡丹皮12份、姜黄12份、升麻12份、乌梅9份、甘草12份。
主要病机:湿(痰)热蕴结、痰瘀互结;治疗方法:清热解毒化湿、泻火、凉血、利咽,益气养阴生津,活血化瘀,化痰散结,敛疮生肌。
将上所述重量份的中药组合物放入砂锅内,第一煎加 600—800 体积份的水,浸泡 20-40 分钟,先用武火煮沸后,再用文火煎 25-35分钟,取药液;第二煎加500-700 体积份的水,先用武火煮沸后,再用文火煎 20-30分钟,取药液;合并两次的药液;所述的重量份的单位以g 计,体积份的单位以 ml计。把两煎药液混匀后分三次服,早、中、晚各服一次,每次300ml,温服;也可按照比例制成散剂、丸剂或者胶囊剂进行服用,每日3次,每次12g。1月1个疗程,3个疗程观察疗效。
资料与方法(一)
一般资料 选择青川县第一人民医院 2019年2月至 2021年6月收治的60例复发性口腔溃疡患者进行临床观察治疗;其中男性31例、女性29例,将以上60人随机分成治疗组30人、对照组30人。签订知情同意书。
对照组的患者采用常规的西药治疗,对照组30例予维生素B 2片10mg,每日3次;甲硝唑片0.2g 口服,每日3次;冰硼散吹患处,每日2~3次;0.2%氯己定漱口液含漱,每日4次。1月1个疗程,1个疗程后观察疗效。
治疗组的患者给予本发明组合物进行治疗。由以下组分的原料制备而成:冬凌草30份、猫爪草12份、瓜蒌12份、薄荷12份、香附12份、麦冬15份、黄芪30份、白术12份、薏苡仁30份、姜黄12份、大黄10份、儿茶5份、熟地黄15份、黄柏9份、玄参15份、牡丹皮12份、姜黄12份、升麻12份、乌梅9份、甘草12份。
每日1剂水煎900ml,每次300ml,每日3次口服;或者制成丸剂,每日3次,每次12g;1月1个疗程,1个疗程后观察疗效。
2、疗效判定标准;
痊愈:疼痛消失,口腔溃疡愈合,全身症状消失,半年无复发;
显效:疼痛消失,溃疡愈合,全身症状消失,3月无复发;
有效:溃疡全部治愈,复发时症状轻、病程短,全身症状减轻;
无效:口腔溃疡与治疗前无明显改变。
3、临床结果如下表:
由上表可见得,本发明中药配方治疗复发性口腔溃疡的有效率优于常规的西药治疗,安全且无毒无副作用,对复发性口腔溃疡可起到有效的治疗作用,能大大缩短康复的时间,还可提高机体免疫力,减少复发。
资料与方法(二)
临床资料
诊断标准
1.慢性咽炎:病程在2个月以上,咽痛,咽干,有异物感或胀闷感或灼热感。检查可见咽部黏膜呈慢性充血,咽后壁淋巴滤泡增生或有扩张的小血管网,或咽侧束肥厚。
2.慢性喉炎:病程在1个月以上,声音嘶哑,讲话费力,不耐多言,喉部干燥,微痛、有黏痰不易略出。检查见声带呈慢性充血,声带肥厚,闭合不全,或声带充血、肥厚,或声带有小结、息肉。
一般资料
选取县第一人民医院于2019年2月~2021年6月收治的129例慢性咽喉炎患者,均符合上述诊断标准。其中慢性咽炎77例,慢性喉炎52例。随机分为中药治疗组和西药对照组。中药治疗组65例,其中慢性咽炎38例,慢性喉炎27例;男22例,女43例;年龄最小者23岁,最大者64岁,平均37.6岁;病程最短者2月,最长者8年。西药对照组64例,其中慢性咽炎39例,慢性喉炎25例。男27例,女37例,年龄最小者19岁,最大者63岁,平均31.8岁;病程最短者2月,最长者5年半。上述资料两组无统计学差异。签到知情同意书。
治疗方法:
中药治疗组:使用本发明组方治疗。药物组成:冬凌草30份、猫爪草12份、瓜蒌12份、薄荷12份、香附12份、麦冬15份、黄芪30份、白术12份、薏苡仁30份、姜黄12份、大黄10份、儿茶5份、熟地黄15份、黄柏9份、玄参15份、牡丹皮12份、姜黄12份、升麻12份、乌梅9份、甘草12份。每日1剂水煎900ml,每次300ml,每日3次口服;或者制成丸剂,每日3次,每次12g; 1月1个疗程,1个疗程后观察疗效。
西药对照组:用西药常规治疗:螺旋霉素0.3g,口服,每日3次(个别患者对螺旋霉素过敏者,改用复方新诺明2片口服,每日2次),溶菌酶30mg口服,每日3次。
观察项目:
观察治疗前后咽痛、咽干、咽部充血和声嘶,声带充血,声带肿胀(小结)等项指标,并用评分法记录,每项指标按轻、中、重程度不同,分别记为1、2、3分,如该项指标为阴性,则记为0分。
结果
疗效标准
慢性咽炎:①痊愈:治疗3周内,咽部症状消失,咽部黏膜充血消失,增生的淋巴滤泡消失或减少,咽侧束肥厚消失。②好转:咽部症状明显减轻,咽黏膜充血、咽后壁淋巴滤泡增生减轻。③无效:咽部症状继续存在,咽部阳性体征无改善。
3.慢性喉炎:①痊愈:治疗3周内,发音恢复正常,检查声带无明显异常,喉部阳性体征消失。②好转:声音嘶哑和其他症状以及喉部阳性体征明显减轻。③无效:声音嘶哑及喉部阳性体征无明显改善。
治疗结果
根据上述评分标准,对患者治疗前后各项主要观察指标进行了详细记录,并对各指标治疗前后得分均数进行组间比较,其结果见附表1。
注:治疗前后与对照组比较:*p≥0.05,**p<0.05,***p<0.01。
根据上述疗效标准,中药治疗组65例,治愈28例,好转37例,无效0例,总有效率为100%;西药对照组64例,治愈4例,好转38例,无效22例,总有效率为65.63%;两组比较,经统计学处理p<0.01. 其结果见附表2。
附表2 两组患者疗效对比[n(%)]
由表中可见,治疗前两组各项观察指标间的组间差异p均≥0.05,说明两组在治疗前各项指标的轻重程度、病变程度基本相同,有可比性。治疗后结果表明,治疗组各项指标的积分均明显低于对照组(p<0.05,p<0.01),说明本发明中药组合物在治疗慢性咽喉炎方面均明显优于西药治疗。
结论:综上所述,本发明中药组合物遵循“三焦焦膜”理论;采用异病同治的方法,同一组合物既能有效治疗复发性口腔溃疡又能很好的治疗慢性咽喉炎;组合物具有清热解毒化湿、泻火、凉血、利咽,益气养阴生津,活血化瘀,化痰散结,敛疮生肌等功效;临床疗效确切;能大大缩短康复的时间,还可提高机体免疫力,减少复发,预防肿瘤并发症;该中药组合物简便、价廉且无毒无副作用;该中药组合物服用方便,可使用现代工艺制备成多种剂型服用,此外还可批量生产,方便推广使用。
Claims (7)
1.一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法,其特征在于,由下述重量/体积份数的各原料药制成:冬凌草10-50份、猫爪草6-15份、瓜蒌10-20份、薄荷6-15份、香附9-15份、麦冬10-20份、黄芪15-50份、白术9-15份、薏苡仁10-50份、姜黄9-15份、大黄6-15份、儿茶3-10份、熟地黄10-20份、黄柏6-15份、玄参9-20份、牡丹皮9-15份、姜黄6-15份、升麻9-15份、乌梅6-15份、甘草9-20份。
2.根据权利要求1所述的治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法,其特征在于,所述各原料药的重量/体积份数优选为:冬凌草30份、猫爪草12份、瓜蒌12份、薄荷12份、香附12份、麦冬15份、黄芪30份、白术12份、薏苡仁30份、姜黄12份、 大黄10份、儿茶5份、熟地黄15份、黄柏9份、玄参15份、牡丹皮12份、姜黄12份、升麻12份、乌梅9份、甘草12份。
3.根据权利要求1-2之一所述的治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法,其特征在于所述中药组合物为:按现有工艺可以制作成口服液、汤、丸、散、胶囊等临床上可以接受的任一制剂。
4.根据权利要求1—2之一所述的治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法,其特征在于将所述重量份的中药组合物放入砂锅内,第一煎加600—800体积份的水,浸泡 20-40分钟,先用武火煮沸后,再用文火煎25-35分钟,取药液;第二煎加500-700体积份的水,先用武火煮沸后,再用文火煎 20-30分钟,取药液;合并两次的药液;所述的重量份的单位g计,体积份的单位以ml计。
5.根据权利要求1—2之一所述的中药组合物颗粒剂的制备方法,其特征在于将所述
重量份的中药组合物运用现有工艺的煎煮、浓缩、干燥、制粒等程序精制成颗粒,封装袋。
6.根据权利要求1—2之一所述的中药组合物蜜丸的制备方法,其特征在于将所述重量份的中药组合物粉碎后,过100 目或者120 目筛制成极细药粉后,再将药粉和蜜按1:1.2—1.8 的重量比制成蜜丸。
7.根据权利要求 1—3 之一所述的中药组合物胶囊剂的制备方法,其特征在于将所述
重量份的中药组合物粉碎后,过100目或者120目筛制成极细药粉,将药粉装入空心胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211344433.XA CN115607646A (zh) | 2022-10-31 | 2022-10-31 | 一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211344433.XA CN115607646A (zh) | 2022-10-31 | 2022-10-31 | 一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115607646A true CN115607646A (zh) | 2023-01-17 |
Family
ID=84876680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211344433.XA Withdrawn CN115607646A (zh) | 2022-10-31 | 2022-10-31 | 一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115607646A (zh) |
-
2022
- 2022-10-31 CN CN202211344433.XA patent/CN115607646A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104399011A (zh) | 一种用于食管癌疼痛的中药组合物及其制备方法 | |
CN104324125B (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法 | |
CN104873446A (zh) | 一种含肉桂油的牙膏 | |
CN111588828A (zh) | 一种治疗新冠病毒和病毒性疾病的中药制剂及制备方法 | |
CN103495072B (zh) | 一种治疗支气管扩张病的中药组合物及其制备方法 | |
CN104998197A (zh) | 一种用于治疗肝癌的中药组合物 | |
CN115607646A (zh) | 一种治疗复发性口腔溃疡和慢性咽喉炎的组合物及制备法 | |
CN105031595A (zh) | 一种治疗钱币状湿疹的中药片剂及其制备方法 | |
CN104189489A (zh) | 一种具有治疗慢性湿疹功效的药剂及其制备方法 | |
CN104645113A (zh) | 一种治疗鼻咽癌的中药制剂及制法 | |
CN106109895A (zh) | 一种治疗肝郁痰火型慢性咽炎的中药组合物及方法 | |
CN106039075A (zh) | 一种治疗肺胃蕴热型慢性咽炎的中药组合物及方法 | |
CN105998979A (zh) | 一种治疗肺肾阴虚型慢性咽炎的中药组合物及方法 | |
CN104606447A (zh) | 一种治疗外感发热的中药制剂 | |
CN104906352A (zh) | 一种治疗虚火上炎型小儿口疮的中药药液及其制备方法 | |
CN105998542A (zh) | 一种治疗急性咽喉炎的中药喷剂及其制备方法 | |
CN104998189A (zh) | 一种治疗风热乘脾型小儿口疮的中药散剂及其制备方法 | |
CN105012789A (zh) | 治疗宫颈癌的组合物及其制备方法 | |
CN104623471A (zh) | 一种治疗胃及十二指肠溃疡的中药乳剂及制备方法 | |
CN104800580A (zh) | 治疗扁桃体炎的中药方剂 | |
CN104840822A (zh) | 治疗中耳炎的中药组合物 | |
CN104840823A (zh) | 一种治疗中耳炎的中药制剂及制法 | |
CN104740019A (zh) | 用于治疗复发性口疮的精油 | |
CN104491264A (zh) | 治疗食道癌的清热解毒剂及制备方法 | |
KR20220001553A (ko) | 역류성 식도염 예방용 청위탕 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230117 |